Search

A VMAT technique using a rotatable tabletop for TBI in supine position is newly applied at UMC Utrecht. We aimed to assess the dose distribution robustness against daily isocenter shifts. The tabletop enables rotation from head-first (HF) to feet-first (FF) supine position while the patient remains immobilized in an individualized whole-body vacuum matrass and a thermoplastic facemask. The treatment plan was optimized on the HF and FF CT-scans, co-registered on the overlapping anatomical region (20 cm longitudinal). Depending on patient-length, 4 to 6 isocenters with overlapping arcs (4 cm longitudinal) were used. Prescription dose (PD) was 12Gy in 6 fractions with mean dose constraints for lungs/kidneys <10Gy and lenses <8Gy. Daily patient-position verification procedure (PV) comprised: pelvic HF-iso3 (CBCT + online corrected); thoracic HF-iso2 (CBCT only, no correction); knee region FF-iso (CBCT + online corrected). Brain HF-iso1 and FF-iso4 or -iso5 (patient length dependent) not imaged. HF (FF) radiation delivery followed HF (FF)-PV. After each fraction, the dose distribution of the first 3 treated patients (length range 110-195 cm) was recalculated applying the registered isocenter corrections/shifts. Then, the 6-fraction rigidly accumulated dose distribution was compared to the original. The maximum shift for HF-iso2 was 0.4 cm lateral, 0.8 cm longitudinal and 0.9 vertical and for the knee region FF-iso 0.7 cm lateral, 0.4 cm longitudinal and 0.5 cm vertical over all patients/fractions. Over all patients, the differences in PTV volume receiving 80%, 90% and 120% PD between accumulated and original dose distribution were <1%, while a +3% V110% PD maximum difference was found. The maximum mean dose difference for lenses, lungs and kidneys between accumulated and original dose distributions was +1.0 Gy, +0.2 Gy and +0.6 Gy, respectively. The dose distribution of the described VMAT technique for TBI, is proven to be robust against daily observed isocenter shifts. [ABSTRACT FROM AUTHOR]

This study evaluated the robustness of multi-isocenter Volumetric Modulated Arc Therapy Total Body Irradiation dose distribution in the overlapping region between the head-first and feet-first computed tomography scans, considering the longitudinal isocenter shifts recorded during treatment delivery. For 15 out of 22 patients, the dose distribution in the overlapping region fulfilled all three the robustness criteria. The overlapping region dose distribution of the remaining 7 cases fulfilled two robustness criteria. The dose distribution was found to be robust against daily recorded longitudinal isocenter shifts, as a consequence of the patient position verification procedure, of up to 16 mm., Competing Interests: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (© 2024 The Author(s).)

Background and Purpose: Daily online adaptation of the clinical target volume (CTV) using MR-guided radiotherapy enables margin reduction of the planning target volume (PTV). This study describes the implementation and initial experience of MR-guided radiotherapy on the 1.5T MR-linac and evaluates treatment time, patient compliance, and target coverage, including an initial assessment of margin reduction., Materials and Methods: Patients were treated on a 1.5T MR-linac (7MV, FFF). At each fraction a 3D T2 weighted (T2w) MR-sequence was acquired on which the CTV was adapted after a deformable registration of the contours from the pre-planning CT scan. Based on the new contours a full online replanning was done after which a new 3D T2w MR-sequence was acquired for position verification. A 5 field Intensity Modulated Radiotherapy (IMRT) plan was delivered., Results: Forty-three patients with rectal cancer were treated with 25 Gy in 5 fractions of which 18 with reduced margins. In total, 204 of 215 fractions were delivered on the MR-linac all of which obtained a clinically acceptable treatment plan. Median in-room time per fraction was 48 min (interquartile range 8). No fractions were canceled or interrupted because of patient intolerance. CTV coverage after margin reduction was good on all post-treatment scans but one due to passing gas., Conclusion: MR-guided radiotherapy using daily full online recontouring and replanning on a 1.5T MR-linac for rectal cancer is feasible and currently takes about 48 min per fraction., (Copyright © 2021 The Authors. Published by Elsevier B.V. All rights reserved.)

Background and Purpose: The promise of the MR-linac is that one can visualize all anatomical changes during the course of radiotherapy and hence adapt the treatment plan in order to always have the optimal treatment. Yet, there is a trade-off to be made between the time spent for adapting the treatment plan against the dosimetric gain. In this work, the various daily plan adaptation methods will be presented and applied on a variety of tumour sites. The aim is to provide an insight in the behavior of the state-of-the-art 1.5 T MRI guided on-line adaptive radiotherapy methods., Materials and Methods: To explore the different available plan adaptation workflows and methods, we have simulated online plan adaptation for five cases with varying levels of inter-fraction motion, regions of interest and target sizes: prostate, rectum, esophagus and lymph node oligometastases (single and multiple target). The plans were evaluated based on the clinical dose constraints and the optimization time was measured., Results: The time needed for plan adaptation ranged between 17 and 485 s. More advanced plan adaptation methods generally resulted in more plans that met the clinical dose criteria. Violations were often caused by insufficient PTV coverage or, for the multiple lymph node case, a too high dose to OAR in the vicinity of the PTV. With full online replanning it was possible to create plans that met all clinical dose constraints for all cases., Conclusion: Daily full online replanning is the most robust adaptive planning method for Unity. It is feasible for specific sites in clinically acceptable times. Faster methods are available, but before applying these, the specific use cases should be explored dosimetrically.